Drug intelligence / Profile preview

mistletoe lectin I

Development stage
Preclinical
Modality
Plant Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Subcutaneous, Intravenous, Intratumoral, Intrapleural
01

Overview

Mistletoe lectin I (ML-1), also known as viscumin or Viscum album agglutinin (VAA), is a biologically active protein isolated from the European mistletoe plant (Viscum album). It is a type II ribosome-inactivating protein composed of two chains: an A-chain with RNA N-glycosidase activity that depurinates 28S rRNA and inhibits protein synthesis (cytotoxic effect), and a B-chain that binds specifically to beta-galactoside residues on cell surfaces. The B-chain facilitates cellular uptake by binding to galactose-containing glycoligands. ML-1 has demonstrated both cytotoxic and immunomodulatory properties in preclinical studies. It can stimulate cytokine secretion by immune cells, increase natural killer cell numbers and activity, enhance macrophage function, and modulate T-cell responses. Mistletoe extracts standardized for ML-1 are used as biological response modifiers in integrative oncology settings; however, robust clinical evidence for antitumor efficacy remains limited[2][5][6][7][8].

Other names
galactoside-specific lectin from mistletoebeta-galactoside-specific lectin 1Viscum album agglutiningalactoside-specific mistletoe lectin
02

Targets

28S rRNA (28S ribosomal RNA)

Beyond the preview

Go deeper on mistletoe lectin I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mistletoe lectin I.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call